Environmental Risk Assessment Preparation for Pharmaceuticals
Synthesize pharmaceutical environmental data into FDA-compliant risk assessments
What You Can Do
This skill helps you synthesize complex environmental toxicology and fate data into cohesive, regulatory-quality Environmental Assessment narratives. You can organize hazard identification, exposure assessment, and risk characterization frameworks; integrate multi-study ecotoxicity evidence; cross-reference FDA/EMA/ICH M7 guidance; and identify data gaps—all while maintaining scientific rigor and compliance consistency required for NDAs, INDs, and BPCIs.
Features
Organizes data flow from hazard identification through exposure assessment to risk characterization
Consolidates ecotoxicity test results, environmental fate studies, and monitoring data into consistent narratives
Cross-references ICH M7, FDA Environmental Assessment Guidance, and EMA CHMP criteria to ensure section completeness
Drafts scientifically-grounded rationales for acute/chronic toxicity, persistence, and bioaccumulation classifications
Structures predicted environmental concentration (PEC) scenarios and exposure pathways into assessment narratives
Flags missing studies, inadequate biodegradation data, or exposure uncertainties requiring follow-up work
Links individual ecotoxicity reports and environmental monitoring results to specific EA sections with proper terminology
Example Output
Input: Raw data including fish acute toxicity (96-h LC₅₀), Daphnia chronic toxicity (21-d NOEC), soil biodegradation study (% mineralization at 28 days), LogPow, and predicted aquatic PEC from wastewater treatment.
Output Example 1 — Hazard Characterization Section: "The aquatic hazard profile was determined based on acute and chronic ecotoxicity studies in three trophic levels. Fish (Danio rerio) acute LC₅₀ of 2.3 mg/L and Daphnia magna 21-day NOEC of 0.15 mg/L indicate Category 1 acute aquatic hazard (meets ≤1 mg/L criterion). Chronic classification is Category 1 based on the NOEC/toxicity ratio to hazard thresholds per GHS Annex 1.A. Ready biodegradability testing showed 38% mineralization at 28 days, indicating non-rapid degradation and persistence concern."
Output Example 2 — Risk Characterization: "Environmental risk is low in aquatic compartments under predicted exposure scenarios. Predicted PEC in surface water (0.08 μg/L) derived from wastewater treatment plant modeling yields PEC/PNEC ratio of 0.002, indicating negligible acute risk. Bioaccumulation potential is limited (BCF <100, Log Kow 1.8), and terrestrial exposure pathways are not expected due to low soil mobility and rapid aqueous phase degradation."
What's Included
- SKILL.md: Full environmental risk assessment protocol with compliance frameworks
- EA Outline Template: Section-by-section structure for NDAs/INDs/BPCIs following FDA guidance
- Ecotoxicity Data Synthesis Checklist: Ensures all relevant studies (fish, Daphnia, algae, bacteria) are integrated
- ICH M7 Cross-Reference Table: Maps assessment elements to specific guideline requirements
- Hazard Classification Justification Framework: Structured format for GHS category rationales with threshold documentation
Who It's For
- Pharmaceutical toxicologists drafting Environmental Assessments for regulatory submissions
- Regulatory affairs professionals preparing NDA/IND environmental chapters
- Pre-clinical/safety scientists synthesizing ecotoxicity study data
- Environmental consultants supporting pharmaceutical companies in EA development
- Quality assurance reviewers validating Environmental Assessment completeness and consistency
Best For
- Organizing and structuring multi-study ecotoxicity datasets into coherent assessment narratives
- Drafting environmental chapters for FDA/EMA submissions with regulatory language and citations
- Synthesizing evidence for aquatic hazard classification and bioaccumulation assessments
- Identifying data gaps and recommending follow-up environmental studies
- Cross-referencing pharmaceutical environmental data against ICH M7 and FDA guidance requirements
You might also like
You can submit tool designs—drawings, specifications, or descriptions—and Claude will evaluate manufacturability constraints, identify potential failure modes using structured frameworks, and recommend cost-reduction opportunities. You'll receive a prioritized report covering structural analysis, production feasibility, material efficiency, and design trade-offs.
by kody-w
You can automate the validation of clinical trial data against protocol specifications, identify discrepancies including missing values, out-of-range results, protocol violations, and CRF inconsistencies. The skill generates audit-ready query documentation, categorizes anomalies by severity and type, resolves root causes systematically, and produces FDA inspection-ready reports that trace every data decision and corrective action for CDISC and regulatory submission.
by kody-w
You can submit raw mass spectrometry observations, instrument parameters, or sample preparation details to Claude and receive targeted diagnostic frameworks that explain anomalous results. Claude systematically generates plausible mechanistic explanations for unexpected protein abundance patterns, quantification inconsistencies, and PTM findings—then helps you design minimal, hypothesis-driven troubleshooting experiments to test them.
by kody-w
You can take unstructured monitoring visit observations and convert them into formal, audit-ready reports that categorize findings by risk level (Critical, Major, Minor), validate protocol compliance, and generate actionable follow-up items with assigned owners and resolution dates. The skill ensures your documentation meets FDA inspection standards and ICH-GCP requirements while creating clear escalation pathways for high-risk issues.
by kody-w
You can validate eCRF and paper CRF datasets against protocol-defined rules, automatically identify data discrepancies (missing fields, out-of-range values, date inconsistencies), generate structured Data Query Forms (DQFs) for site clarification, track resolution status, and create audit-ready compliance documentation that meets FDA 21 CFR Part 11 and GCP requirements. This workflow reduces manual validation time while ensuring 100% traceability and regulatory readiness for inspections.
by kody-w
Get comprehensive PCB design analysis covering power delivery networks, signal integrity, thermal management, and manufacturing constraints. Claude identifies potential issues early and provides specific, actionable optimization recommendations to reduce cost, improve reliability, and accelerate time-to-market. Suitable for designs from initial concept through production-ready layouts.
by kody-w
You consolidate parallel data streams from preclinical toxicology studies (clinical pathology, histopathology, body weight changes, organ weights, clinical observations, mortality) into coherent regulatory-compliant narratives. This skill synthesizes findings across 6–12 endpoints simultaneously, identifies NOAEL/LOAEL with biological justification, determines safety margins, interprets species-specific or sex-specific signals, and produces Results & Discussion sections that satisfy FDA/EMA reviewers while supporting appropriate dosing decisions for IND-enabling studies.
by kody-w
This skill systematically analyzes your product designs to identify manufacturability issues early, saving costly revisions and manufacturing delays. It evaluates geometry, material selection, tolerances, assembly feasibility, and production process constraints. You get actionable feedback on cost drivers, process risks, and design optimizations before committing to production.
by kody-w